Therapeutic effects of target artery infusion of verapamil and chemotherapy drugs on advanced non-small cell lung cancer
10.3760/cma.j.cn112152-20190724-00461
- VernacularTitle:靶动脉灌注维拉帕米和化疗药物治疗中晚期非小细胞肺癌的疗效分析
- Author:
Yufei TAN
1
;
Hengxiang MA
;
Bing ZHAO
;
Huaru ZHANG
Author Information
1. 驻马店市中心医院呼吸内科一病区 463000
- Keywords:
Neoplasms, non-small cell lung;
Target arterial perfusion;
Verapamil;
Immune function;
Prognosis
- From:
Chinese Journal of Oncology
2020;42(6):486-490
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effects of targeted artery perfusion of verapamil and chemotherapy drugs on advanced non-small cell lung cancer (NSCLC).Methods:Sixty patients with advanced NSCLC who were admitted to the Central Hospital of Zhumadian from April 2016 to April 2018 were selected as the research subjects. They were divided into the observation group (26 cases) and the control group (34 cases) according to the treatment method. Patients in the observation group were treated with targeted artery perfusion of verapamil and chemotherapy drugs while the control group were treated with target artery perfusion of chemotherapy drugs alone.Both groups were treated continuously for more than 2 months. The short-term curative effect, adverse reactions, changes in immune function, levels of serum tumor markers and Karnofsky Performance Scale (KPS) scores before and after treatment as well as the prognosis were compared between the two groups.Results:The response rate and control rate in the observation group were 80.8% and 96.2%, higher than 55.9% and 76.5% in the control group ( P<0.05). After treatment, CD4 + levels and CD4 + /CD8 + in the observation group were (25.43±2.76)% and (0.88±0.11), lower than (27.56±2.79)% and (0.95±0.13) in the control group ( P<0.05). After treatment, serum levels of CEA and CA50 in the observation group were (11.57±2.32)ng/ml and (16.62±3.28)U/ml, also lower than (15.87±2.66)ng/ml and (20.31±3.42)U/ml in the control group ( P<0.05). There was no significant difference in adverse reactions between the two groups ( P>0.05). After treatment, KPS score of the observation group was (81.44±2.76) points, higher than (79.62±2.38) points of the control group ( P<0.05). The median survival time and progression-free median survival time of the observation group were 16.0 months and 7.5 months, respectively, significantly better than 10.0 months and 5.0 months of the control group ( P<0.05). Conclusions:The treatment with target arterial perfusion of verapamil and chemotherapy drugs for advanced NSCLC can effectively improve the short-term curative effect, reduce serum levels of tumor markers, improve life quality and prolong the survival time. However, it has a certain inhibitory effect on the patient′s immune function.
